Australia's TGA Updates Medicinal Cannabis Access Guidelines for Pediatric Patients Under Special Access Scheme

Key Takeaways

• TGA has clarified requirements for healthcare practitioners to access Schedule 8 medicinal cannabis for patients under 18 years old
• Updated guidance covers Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways for Category 2-5 cannabis medicines
• New framework provides clearer regulatory pathway for pediatric medicinal cannabis access in Australia

---

The Therapeutic Goods Administration (TGA) has issued updated guidance clarifying requirements for healthcare practitioners seeking to access medicinal cannabis products for pediatric patients under 18 years of age through established regulatory pathways.

Regulatory Framework for Pediatric Cannabis Access

The updated guidance specifically addresses applications under the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways for Category 2, 3, 4, and 5 medicinal cannabis medicines, which are classified as Schedule 8 controlled substances under Australian law.

Cannabis-based therapeutic products remain available through these specialized access routes, providing healthcare practitioners with regulated pathways to obtain unapproved therapeutic goods for patients with serious medical conditions where conventional treatments have proven inadequate.

IntelligenceRegulatory Impact▾

TGA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in Asia-Pacific. Regulatory relevance reads medium for pharmaceutical intelligence. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.

Clinical and Market Implications

The clarified requirements are expected to streamline the application process for healthcare practitioners while maintaining strict regulatory oversight for pediatric cannabis prescriptions. This development reflects Australia’s evolving approach to medicinal cannabis regulation, balancing patient access with safety considerations for vulnerable populations.

The guidance encompasses the complete therapeutic development pathway, including discovery, product design, clinical trials, and naming conventions for medicinal cannabis products. This comprehensive approach aims to support both current patient access and future therapeutic development in the Australian market.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.

Regulatory Context

Australia has maintained a cautious but progressive stance on medicinal cannabis regulation since legalizing therapeutic use in 2016. The TGA’s updated guidance represents continued refinement of the regulatory framework, particularly for pediatric applications where additional safety considerations apply.

Healthcare practitioners must navigate specific documentation and justification requirements when applying for access to these controlled therapeutic goods, with the TGA maintaining oversight to ensure appropriate clinical use and patient safety standards.

---

Frequently Asked Questions

What does this mean for pediatric patients needing medicinal cannabis?

The updated TGA guidance provides clearer pathways for healthcare practitioners to access medicinal cannabis for patients under 18, potentially improving access while maintaining safety oversight.

Which medicinal cannabis categories are covered by the new guidance?

The guidance covers Category 2, 3, 4, and 5 medicinal cannabis medicines, all classified as Schedule 8 controlled substances under Australian regulation.

How does this compare to adult medicinal cannabis access in Australia?

While adults can access medicinal cannabis through similar SAS and AP pathways, pediatric access requires additional documentation and justification due to enhanced safety considerations for patients under 18.

Related coverage

• TGA Australia drug approval pharmaceutical: what the regulator is
• PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open
• NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access